Efficacy and safety of interleukin inhibitors in the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.
Secukinumab 150 mg linked to higher risk of adverse events than placebo
Efficacy and safety of interleukin inhibitors in the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.
Psoriasis is a relapsing inflammatory skin disease that significantly impacts patients' quality of life, particularly those with moderate-to-severe lesions, which also impose considerable psychological stress.
This study aims to evaluate the clinical efficacy and safety of biologics, providing guidance for clinical application.
We searched PubMed, Cochrane Library, EMBASE, and Web of Science from inception to May 29, 2024, and conducted an updated supplementary search from May 30, 2024 to April 25, 2026 to identify randomized controlled trials (randomized controlled trials) assessing the efficacy and safety of IL-23/IL-17 inhibitors in treating moderate-to-severe plaque psoriasis.
higher odds of side effects than placebo
The meta-analysis results showed that several regimens, including Guselkumab 200 mg, Secukinumab 300 mg, and Brodalumab 210 mg, ranked highly for PASI 75 and PASI 90 at specific follow-up time points; however, ranking patterns varied across outcomes and follow-up durations.
Additionally, Tildrakizumab 100 mg and Tildrakizumab 200 mg showed high SUCRA values for achieving cleared or almost cleared skin and reducing the Dermatology Life Quality Index (Dermatology Life Quality Index) score at most follow-up time points.
This network meta-analysis provides regimen-specific comparative evidence for short-term efficacy and safety of IL-23/IL-17 inhibitors.
Treatment rankings should be interpreted within each outcome and follow-up time point, together with effect estimates, safety profiles, and the amount of supporting evidence.